Iron overload and non-alcoholic fatty liver disease

被引:108
|
作者
Datz, Christian [1 ,2 ]
Mueller, Elena [2 ]
Aigner, Elmar [2 ,3 ]
机构
[1] Paracelsus Med Univ, Hosp Oberndorf, Dept Internal Med, Salzburg, Austria
[2] Paracelsus Med Univ, Obes Res Unit, Salzburg, Austria
[3] Paracelsus Med Univ, Dept Med 1, Salzburg, Austria
关键词
Hepcidins; Iron overload; Metabolic syndrome X; Non-alcoholic fatty liver disease; CARBOHYDRATE-INTOLERANT PATIENTS; SERUM FERRITIN CONCENTRATION; REV-ERB-ALPHA; INSULIN-RESISTANCE; OXIDATIVE STRESS; METABOLIC SYNDROME; HEREDITARY HEMOCHROMATOSIS; HEPCIDIN TRANSCRIPTION; HEPATOMA-CELLS; CLINICAL-TRIAL;
D O I
10.23736/S0391-1977.16.02565-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately one third of patients with non-alcoholic fatty liver disease (NAFLD) show signs of disturbed iron homeostasis as indicated by elevated serum ferritin with normal or mildly elevated transferrin saturation. Mild hepatic iron deposition is the typical histological finding in these subjects and the term "dysmetabolic iron overload syndrome (DIOS)" is now used to describe this syndrome. From a clinical point of view, excess iron likely aggravates the natural course of NAFLD with regard to liver-related endpoints and extrahepatic disease complications although sound evidence is still lacking. The detrimental effect of iron is attributed to its capability to catalyse the formation of toxic hydroxyl radicals resulting in cellular damage. Conversely, reduction of body iron restores insulin sensitivity, and epidemiological evidence suggests that it delays the onset of complications such as T2DM, cardiovascular disease and also advanced liver disease. Iron accumulation in NAFLD is mainly due to inhibition of iron mobilisation from hepatocytes and Kupffer cells. Impaired iron export is related to inflammation and metabolic derangements that appear to impact on iron regulators, such as hepcidin, ferroportin and to a lesser degree on transferrin receptor, ferritin or copper. This review summarizes the current understanding of the role of iron in NAFLD.
引用
收藏
页码:173 / 183
页数:11
相关论文
共 50 条
  • [21] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [22] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [23] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [24] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [25] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [26] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [27] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [28] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [29] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747
  • [30] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Eslami, Layli
    Merat, Shahin
    Malekzadeh, Reza
    Nasseri-Moghaddam, Siavosh
    Aramin, Hermineh
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):